Cart
sales@molnova.com
Losmapimod
CAS No. 585543-15-3
Losmapimod( GSK-AHAB | GW856553X | SB856553 | GW 856553X | SB 856553 )
Catalog No. M15150 CAS No. 585543-15-3
Losmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 27 | In Stock |
|
| 5MG | 43 | In Stock |
|
| 10MG | 64 | In Stock |
|
| 25MG | 128 | In Stock |
|
| 50MG | 213 | In Stock |
|
| 100MG | 385 | In Stock |
|
| 500MG | 872 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLosmapimod
-
NoteResearch use only, not for human use.
-
Brief DescriptionLosmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
-
DescriptionLosmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively; displays no significant activity for p38γ, p38δ (<25% inhibition at 10 uM), and COX-2; significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation in rat model of cardiovascular disease.Ischemia Phase 3 Clinical(In Vitro):In the spontaneously hypertensive stroke-prone rat (SHR-SP), chronic treatment with GSK-AHAB significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1β (IL-1β).
-
In Vitro——
-
In VivoIn the spontaneously hypertensive stroke-prone rat (SHR-SP), chronic treatment with GSK-AHAB significantly and dose-dependently improves survival, endothelial-dependent and -independent vascular relaxation, and indices of renal function, and it attenuates dyslipidemia, hypertension, cardiac remodeling, plasma renin activity (PRA), aldosterone, and interleukin-1β (IL-1β).
-
SynonymsGSK-AHAB | GW856553X | SB856553 | GW 856553X | SB 856553
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38α|p38β
-
Research AreaCardiovascular Disease
-
IndicationIschemia
Chemical Information
-
CAS Number585543-15-3
-
Formula Weight383.4591
-
Molecular FormulaC22H26FN3O2
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 58 mg/mL
-
SMILESO=C(C1=CC=C(C2=CC(C(NC3CC3)=O)=CC(F)=C2C)N=C1)NCC(C)(C)C
-
Chemical Name3-Pyridinecarboxamide, 6-[5-[(cyclopropylamino)carbonyl]-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Willette RN, et al. J Pharmacol Exp Ther. 2009 Sep;330(3):964-70.
2. Cheriyan J, et al. Circulation. 2011 Feb 8;123(5):515-23.
3. Lomas DA, et al. J Clin Pharmacol. 2012 Mar;52(3):416-24.
molnova catalog
related products
-
Darizmetinib
Darizmetinib (HRX215, HRX-0215) is an MKK4 inhibitor. Inhibition of MKK4 leads to enhancement of the MKK7 and JNK1 signaling pathways, thereby activating the transcription factors ATF2 and ELK1, promoting cell proliferation and liver regeneration.
-
Acumapimod
An orally active, potent p38 MAPK inhibitor that potently inhibits ex vivo LPS‐induced TNFα secretion with an IC50 of 44 ng/mL (115 nM).
-
SC-806
A potent, orally active p38 MAPK inhibitor with IC50 of 50 nM.
